180 related articles for article (PubMed ID: 30947657)
41. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
[TBL] [Abstract][Full Text] [Related]
42. The clinical significance and biological function of lncRNA SOCAR in serous ovarian carcinoma.
Guo Q; Wang L; Zhu L; Lu X; Song Y; Sun J; Wu Z; Shi J; Wang Z; Zhou X
Gene; 2019 Sep; 713():143969. PubMed ID: 31299360
[TBL] [Abstract][Full Text] [Related]
43. Long non-coding RNA BACE1-AS is a novel target for anisomycin-mediated suppression of ovarian cancer stem cell proliferation and invasion.
Chen Q; Liu X; Xu L; Wang Y; Wang S; Li Q; Huang Y; Liu T
Oncol Rep; 2016 Apr; 35(4):1916-24. PubMed ID: 26783004
[TBL] [Abstract][Full Text] [Related]
44. PVT1 is a stress-responsive lncRNA that drives ovarian cancer metastasis and chemoresistance.
Tabury K; Monavarian M; Listik E; Shelton AK; Choi AS; Quintens R; Arend RC; Hempel N; Miller CR; Györrfy B; Mythreye K
Life Sci Alliance; 2022 Nov; 5(11):. PubMed ID: 35820706
[TBL] [Abstract][Full Text] [Related]
45. Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.
Mouraviev V; Lee B; Patel V; Albala D; Johansen TE; Partin A; Ross A; Perera RJ
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):14-20. PubMed ID: 26503110
[TBL] [Abstract][Full Text] [Related]
46. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
Fan CN; Ma L; Liu N
J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
[TBL] [Abstract][Full Text] [Related]
47. Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
Filippov-Levy N; Cohen-Schussheim H; Tropé CG; Hetland Falkenthal TE; Smith Y; Davidson B; Reich R
Gynecol Oncol; 2018 Mar; 148(3):559-566. PubMed ID: 29310950
[TBL] [Abstract][Full Text] [Related]
48. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.
Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y
Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409
[TBL] [Abstract][Full Text] [Related]
49. Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer.
Fu Y; Biglia N; Wang Z; Shen Y; Risch HA; Lu L; Canuto EM; Jia W; Katsaros D; Yu H
Gynecol Oncol; 2016 Dec; 143(3):642-649. PubMed ID: 27667152
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic value of non-coding RNAs in ovarian cancer.
Sun N; Liu S; Chen A
J Obstet Gynaecol; 2022 Nov; 42(8):3416-3423. PubMed ID: 36476021
[TBL] [Abstract][Full Text] [Related]
51. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
Wang Z; Liu Z; Wu S
Oncotarget; 2017 May; 8(19):31465-31477. PubMed ID: 28415557
[TBL] [Abstract][Full Text] [Related]
52. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
[TBL] [Abstract][Full Text] [Related]
53. Ginsenoside 20(S)-Rg3 Prevents PKM2-Targeting miR-324-5p from H19 Sponging to Antagonize the Warburg Effect in Ovarian Cancer Cells.
Zheng X; Zhou Y; Chen W; Chen L; Lu J; He F; Li X; Zhao L
Cell Physiol Biochem; 2018; 51(3):1340-1353. PubMed ID: 30481782
[TBL] [Abstract][Full Text] [Related]
54. Up-regulation of long non-coding RNA SNHG20 promotes ovarian cancer progression via Wnt/β-catenin signaling.
He S; Zhao Y; Wang X; Deng Y; Wan Z; Yao S; Shen H
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29101241
[TBL] [Abstract][Full Text] [Related]
55. An Immune-Related lncRNA Pairing Model for Predicting the Prognosis and Immune-Infiltrating Cell Condition in Human Ovarian Cancer.
Zhang X; Yang Q
Biomed Res Int; 2022; 2022():3168408. PubMed ID: 36033566
[TBL] [Abstract][Full Text] [Related]
56. The role of membrane transporters in ovarian cancer chemoresistance and prognosis.
Cerovska E; Elsnerova K; Vaclavikova R; Soucek P
Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):741-753. PubMed ID: 28511565
[TBL] [Abstract][Full Text] [Related]
57. Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer.
Li J; Wang W; Xia P; Wan L; Zhang L; Yu L; Wang L; Chen X; Xiao Y; Xu C
Int J Cancer; 2018 Nov; 143(9):2150-2160. PubMed ID: 29707762
[TBL] [Abstract][Full Text] [Related]
58. Profile and validation of dysregulated long non‑coding RNAs and mRNAs in ovarian cancer.
Lu YM; Wang Y; Liu SQ; Zhou MY; Guo YR
Oncol Rep; 2018 Nov; 40(5):2964-2976. PubMed ID: 30132558
[TBL] [Abstract][Full Text] [Related]
59. Functions and Mechanisms of Long Noncoding RNAs in Ovarian Cancer.
Ren C; Li X; Wang T; Wang G; Zhao C; Liang T; Zhu Y; Li M; Yang C; Zhao Y; Zhang GM
Int J Gynecol Cancer; 2015 May; 25(4):566-9. PubMed ID: 25756403
[TBL] [Abstract][Full Text] [Related]
60. Integrated analysis of long non-coding RNA‑associated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma.
Sui J; Li YH; Zhang YQ; Li CY; Shen X; Yao WZ; Peng H; Hong WW; Yin LH; Pu YP; Liang GY
Int J Oncol; 2016 Nov; 49(5):2023-2036. PubMed ID: 27826625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
